Is KPTI stock headed for a breakdown?
If the stock moves under this level, a breakdown could occur. KPTI is a pharmaceutical company. The company focused on the discovery, development, and commercialization of medicines with the goal of improving the lives of patients with cancer.
Should you buy Karyopharm Therapeutics (KPTI) stock?
The stock option was granted as an inducement m Investors need to pay close attention to Karyopharm Therapeutics (KPTI) stock based on the movements in the options market lately. In this daily bar chart of KPTI, below, we can see that prices have been under selling pressure since February.
Is Pfizer stock up or down over the last month?
However, Pfizer stock is up over the last month while the other two vaccine stocks have plunged more than 20%. Cuba Gooding, Jr.'s character in the movie Jerry Maguire had a famous line that seems applicable for Pfizer, BioNTech, and Moderna: "Show me the money."
Is KPTI a buy?
Out of 6 analysts, 1 (16.67%) are recommending KPTI as a Strong Buy, 1 (16.67%) are recommending KPTI as a Buy, 4 (66.67%) are recommending KPTI as a Hold, 0 (0%) are recommending KPTI as a Sell, and 0 (0%) are recommending KPTI as a Strong Sell. What is KPTI's earnings growth forecast for 2022-2024?
Why is karyopharm stock down?
Karyopharm Therapeutics Inc (NASDAQ: KPTI) stock plunged after an update on its supplemental New Drug Application submission based on the Phase 3 SIENDO study data of selinexor as front-line maintenance therapy following chemotherapy in advanced or recurrent endometrial cancer.
Why Karyopharm Therapeutics Stock Was a Winner on Wednesday
Karyopharm Therapeutics (KPTI) Q4 2021 Earnings Call Transcript
An analyst upgrade that followed much better-than-expected quarterly results put some real zip into the biotech's stock.
What is Karyopharm Therapeutics?
At this time, I would like to welcome everyone to the Karyopharm Therapeutics' fourth quarter and full-year 2021 financial results conference call.
Is XPOVIO a selective inhibitor?
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Compensation Committee of Karyopharm's Board of Directors granted stock options to purchase an aggregate of 74,600 shares of Karyopharm's common stock to 11 newly-hired employees, ...
NYSE: PFE
(Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that three new strength tablets for XPOVIO, the Company's first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) medicine, are now commercially available. The availability of these additional strength tablets follows a U.S. Food & Drug Administration (FDA) approval on April 15, 2021. In addition to the original 20 mg strength tablets, XPOVIO is now a
NYSE: PFE
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
So what
So why are these vaccine stocks tumbling today? Investors appear to be looking past the current surge in COVID-19 cases and expect a future where fewer vaccine doses are administered.
Now what
Investors should always look forward. And the number of COVID-19 vaccine doses sold by Pfizer, BioNTech, and Moderna could very well decline significantly after 2022 (or perhaps 2023).
Premium Investing Services
Cuba Gooding, Jr.'s character in the movie Jerry Maguire had a famous line that seems applicable for Pfizer, BioNTech, and Moderna: "Show me the money." The main thing for investors to watch with all three companies is the money -- in particular, supply deals for COVID-19 vaccines for beyond 2022.
